grants_govPAR-27-065
Open
NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
- Response deadline
- Mar 9, 2029 Due in 920 days
- Date posted
- Aug 31, 2026
- Source
- Open notice
Description
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS and may include studies of small molecules, biologics, devices as well as surgical, behavioral, diet-based, or rehabilitation therapies. Studies addressing neurological diseases and care across the lifespan are highly encouraged. This notice invites both early- and middle-phase exploratory clinical trials as well as later phase confirmatory Phase 3 or comparative effectiveness clinical trials.
Classifications
- NAICS93.853
Documents (1)
- PAR-27-065-Full-Announcement.htmltext/html;charset=UTF-8161 KBNot yet available
Contacts
Similar contracts
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)Due Sep 28, 2026
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)Due Apr 5, 2029
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)Due Nov 10, 2026
- Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)Due Oct 8, 2027
- HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)Due Jul 16, 2026